ENDRA Life Sciences (NDRA) Long-Term Deferred Tax (2019 - 2023)

ENDRA Life Sciences has disclosed Long-Term Deferred Tax across 4 years of filings, most recently posting $21.2 million for Q4 2023.

• In Q4 2023, Long-Term Deferred Tax rose 14.2% year-over-year to $21.2 million; the TTM figure through Dec 2023 stood at $21.2 million (up 14.2% YoY), while the FY2023 annual figure was $21.2 million, up 14.2% from the prior year.
• Long-Term Deferred Tax climbed to $21.2 million in Q4 2023, from $18.5 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for NDRA reached as high as $21.2 million in Q4 2023 and fell as low as $7.8 million in Q4 2019.
• The 4-year median for Long-Term Deferred Tax is $16.2 million (2021), against an average of $15.3 million.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax jumped 34.05% — and 2023, when it increased 14.2%.
• A 4-year view of Long-Term Deferred Tax shows it stood at $7.8 million in 2019, then jumped by 76.87% to $13.8 million in 2021, then surged by 34.05% to $18.5 million in 2022, then grew by 14.2% to $21.2 million in 2023.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $21.2 million, $18.5 million, and $13.8 million for Q4 2023, Q4 2022, and Q4 2021 respectively.